CCCC
NASDAQC4 Therapeutics Inc.
News · 26 weeks43+100%
2025-10-262026-04-19
Mix2890d
- Other14(50%)
- Insider9(32%)
- SEC Filings5(18%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche ((SIX: RO, ROP, OTCQX:RHHBY) to ad
- INSIDERSEC Form 4 filed by Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- PRC4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple MyelomaWATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed with cemsidomide, an oral IKZF1/3 degrader, in a Phase 1b trial evaluating cemsidomide and dexamethasone in combination with elranatamab (ELREXFIO®), an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody, for the treatment of relapsed/refractory multiple myeloma (RRMM). "Data from our Phase 1 trial support cemsidomide as a potential best-in-class, next-generation IKZF1/3 degrader and the initiation of this Phase 1b tri
- PRC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on March 9, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Li
- PRNext-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic
- SECSEC Form S-8 filed by C4 Therapeutics Inc.S-8 - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form 10-K filed by C4 Therapeutics Inc.10-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsCemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a cl
- PRC4 Therapeutics to Participate in Upcoming March ConferencesWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences. TD Cowen 46th Annual Healthcare Conference: Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts. Barclays 28th Annual Global Healthcare Conference: Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida. The live webcasts will be available on the Investors section o
- PRC4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple MyelomaEnrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). "Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety
- INSIDERChief Business Officer Boyle Scott N was granted 200,000 shares, converted options into 25,950 shares and covered exercise/tax liability with 9,004 shares, increasing direct ownership by 177% to 298,801 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERChief Scientific Officer Mahaney Paige was granted 240,000 shares, converted options into 7,050 shares and covered exercise/tax liability with 2,446 shares, increasing direct ownership by 239% to 336,910 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERPresident & CEO Hirsch Andrew was granted 700,000 shares, converted options into 102,125 shares and covered exercise/tax liability with 48,211 shares, increasing direct ownership by 154% to 1,074,934 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERChief People Officer Schick Kelly converted options into 25,950 shares, covered exercise/tax liability with 9,004 shares and was granted 200,000 shares, increasing direct ownership by 175% to 299,881 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERChief Medical Officer Reyno Leonard was granted 240,000 shares, converted options into 30,950 shares and covered exercise/tax liability with 16,579 shares, increasing direct ownership by 143% to 379,803 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERChief Accounting Officer Mossler Mark was granted 56,980 shares, converted options into 9,420 shares and covered exercise/tax liability with 3,268 shares, increasing direct ownership by 295% to 71,916 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERChief Financial Officer Adams Kendra was granted 240,000 shares, converted options into 34,700 shares and covered exercise/tax liability with 17,244 shares, increasing direct ownership by 137% to 385,098 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)